BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap. I rate BLLN stock as Buy.
Why BLLN Stock advanced +0.74% Today — RQD Quant Desk Flash
BillionToOne Inc. (BLLN) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Why BLLN Stock advanced +0.74% Today — RQD Quant Desk Flash
BillionToOne Inc. (BLLN) advanced +0.74% to $114.84 as options desks priced 57% call premium vs. 43% put protection around the $113 max-pain magnet. Solid 68% profit margin (3% return on capital), mixed timing at 185x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 60% of its 52-week range ($61.96 – $150.44) with RSI-14 at 59.5 (BULLISH MOMENTUM).
- ▸Whale Options Positioning: $2.6M in bullish call flow vs. $1.9M in put flow (Put/Call 0.76x, implied earnings swing ±7%).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 68.3% gross margin and $15.7M annual free cash flow.
Baxter (BAX) delivered earnings and revenue surprises of +13.73% and +2.48%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Investing.com-- Several specialty lab companies are set to report third-quarter results in early November, with analysts at BTIG outlining key metrics and expectations for the sector’s leading names. The firm has identif
BillionToOne (BLLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, to
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live BLLN Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
BLLN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +100.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BLLN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BLLN. Explore sector supply chains on /butterfly.
BLLN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BLLN stock moving today?
Why BLLN Stock advanced +0.74% Today — RQD Quant Desk Flash. Solid 68% profit margin (3% return on capital), mixed timing at 185x P/E—hold if owned, no rush to chase.